BR112023000648A2 - Ensaio à base de sangue para detectar tauopatia ou doença amiloidogênica - Google Patents

Ensaio à base de sangue para detectar tauopatia ou doença amiloidogênica

Info

Publication number
BR112023000648A2
BR112023000648A2 BR112023000648A BR112023000648A BR112023000648A2 BR 112023000648 A2 BR112023000648 A2 BR 112023000648A2 BR 112023000648 A BR112023000648 A BR 112023000648A BR 112023000648 A BR112023000648 A BR 112023000648A BR 112023000648 A2 BR112023000648 A2 BR 112023000648A2
Authority
BR
Brazil
Prior art keywords
tau
antibody
tauopathy
amyloidogenic disease
blood
Prior art date
Application number
BR112023000648A
Other languages
English (en)
Inventor
C Kolb Hartmuth
Triana-Baltzer Gallen
Saad Ziad
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of BR112023000648A2 publication Critical patent/BR112023000648A2/pt

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2440/00—Post-translational modifications [PTMs] in chemical analysis of biological material
    • G01N2440/14—Post-translational modifications [PTMs] in chemical analysis of biological material phosphorylation
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/50—Determining the risk of developing a disease

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Physical Vapour Deposition (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

ENSAIO À BASE DE SANGUE PARA DETECTAR TAUOPATIA OU DOENÇA AMILOIDOGÊNICA. A presente invenção refere-se a um método para detectar tau p217+ em amostras à base de sangue de um indivíduo com alta sensibilidade, exatidão e precisão. O ensaio compreende colocar uma amostra em contato com um anticorpo de captura direcionado contra um epítopo de tau p217+ para ligar o anticorpo de captura aos peptídeos tau p217+ no plasma para formar complexos de anticorpo-peptídeo e colocar separadamente os complexos de anticorpo-peptídeo em contato com um an-ticorpo de detecção para ligar o anticorpo de detecção aos complexos de anticorpo-peptídeo. A quantidade de tau p217+ é determinada pela detecção do anticorpo de detecção. A quantidade de tau p217+ detectada é usada para determinar se o indivíduo tem tauopatia ou está em risco de desenvolver tauopatia, ou se o indivíduo tem doença amiloidogênica ou está em risco de desenvolver doença amiloidogênica quando a quantidade de peptídeos tau p217+ estiver acima de um valor-limite predeterminado. O método tem sensibilidade melhorada de modo que o valor-limite predeterminado esteja acima de um limite inferior de quantificação e/ou limite inferior de detecção do ensaio.
BR112023000648A 2020-07-14 2021-07-14 Ensaio à base de sangue para detectar tauopatia ou doença amiloidogênica BR112023000648A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202062705759P 2020-07-14 2020-07-14
US202163200399P 2021-03-04 2021-03-04
PCT/EP2021/069595 WO2022013286A1 (en) 2020-07-14 2021-07-14 Blood-based assay for detecting tauopathy or amyloidogenic disease

Publications (1)

Publication Number Publication Date
BR112023000648A2 true BR112023000648A2 (pt) 2023-04-25

Family

ID=77168226

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112023000648A BR112023000648A2 (pt) 2020-07-14 2021-07-14 Ensaio à base de sangue para detectar tauopatia ou doença amiloidogênica

Country Status (12)

Country Link
US (1) US20220018857A1 (pt)
EP (1) EP4182697A1 (pt)
JP (1) JP2023533806A (pt)
KR (1) KR20230037647A (pt)
CN (1) CN116348769A (pt)
AU (1) AU2021309020A1 (pt)
BR (1) BR112023000648A2 (pt)
CA (1) CA3189577A1 (pt)
IL (1) IL299822A (pt)
MX (1) MX2023000695A (pt)
TW (1) TW202217316A (pt)
WO (1) WO2022013286A1 (pt)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023242336A1 (en) 2022-06-15 2023-12-21 Janssen Pharmaceutica Nv Blood-based screening of subjects for a clinical trial for treatment of tauopathy or amyloidogenic disease

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201636048A (zh) * 2009-12-21 2016-10-16 建南德克公司 抗體調配物
ITMI20120814A1 (it) * 2012-05-11 2013-11-12 Diego Dolcetta Somministrazione intratecale, preferibilmente intraventricolare, di inibitori di mtor per la terapia di alcune malattie neurodegenerative, neuro-infiammatorie, neuro-oncologiche
WO2014011972A1 (en) * 2012-07-13 2014-01-16 Bristol-Myers Squibb Company Tau immunoassay
US8980270B2 (en) * 2013-01-18 2015-03-17 Ipierian, Inc. Methods of treating a tauopathy
US11698378B2 (en) * 2015-09-25 2023-07-11 Children's Medical Center Corporation Methods and compositions for tauopathy diagnosis and treatment
CA3045294A1 (en) * 2016-12-07 2018-06-14 Genentech, Inc. Anti-tau antibodies and methods of use
JOP20180021A1 (ar) * 2017-03-16 2019-01-30 Janssen Biotech Inc الأجسام المضادة لتكتلات خيوط بروتين تاو (tau) الحلزونية المزدوجة واستخداماتها
WO2019171258A1 (en) * 2018-03-05 2019-09-12 Janssen Pharmaceutica Nv Assays to detect neurodegeneration
WO2020223279A1 (en) * 2019-04-29 2020-11-05 Voyager Therapeutics, Inc. VECTORIZED ANTIBODIES (vAb) AND USES THEREOF

Also Published As

Publication number Publication date
IL299822A (en) 2023-03-01
TW202217316A (zh) 2022-05-01
AU2021309020A1 (en) 2023-03-09
JP2023533806A (ja) 2023-08-04
WO2022013286A1 (en) 2022-01-20
MX2023000695A (es) 2023-04-20
CN116348769A (zh) 2023-06-27
EP4182697A1 (en) 2023-05-24
KR20230037647A (ko) 2023-03-16
US20220018857A1 (en) 2022-01-20
CA3189577A1 (en) 2022-01-20

Similar Documents

Publication Publication Date Title
Spencer et al. Current status and performance goals for serum thyrotropin (TSH) assays
Persijn et al. Evaluation of a new set of automated chemiluminescense assays for anticardiolipin and anti-beta2-glycoprotein I antibodies in the laboratory diagnosis of the antiphospholipid syndrome
BR112015021199A2 (pt) método para determinar se uma infeção é bacteriana e/ou viral, dispositivo de fluxo lateral para detecção de um analito em uma amostra, e, dispositivo para detecção de um marcador bacteriano e/ou viral em uma amostra
Herrmann The measurement of 25-hydroxy vitamin D–an analytical challenge
Kuno et al. LecT-Hepa: A triplex lectin–antibody sandwich immunoassay for estimating the progression dynamics of liver fibrosis assisted by a bedside clinical chemistry analyzer and an automated pretreatment machine
BR112023000648A2 (pt) Ensaio à base de sangue para detectar tauopatia ou doença amiloidogênica
Delille et al. Effect of protein binding on unbound atazanavir and darunavir cerebrospinal fluid concentrations
Wang et al. Development of a novel chemiluminescence immunoassay for the detection of procalcitonin
Zhang et al. Reference intervals of alpha-fetoprotein and carcinoembryonic antigen in the apparently healthy population
MX2021005902A (es) Metodo basado en celulas para determinar una actividad de la toxina botulinica.
Ryu et al. Performance evaluation of serum PIVKA‐II measurement using HISCL‐5000 and a method comparison of HISCL‐5000, LUMIPULSE G1200, and ARCHITECT i2000
Giovanella et al. High-sensitivity human thyroglobulin (hTG) immunoradiometric assay in the follow-up of patients with differentiated thyroid cancer
Walker et al. Lipaemia: causes, consequences and solutions
Nguyen et al. Capillary electrophoresis-laser-induced fluorescence (CE-LIF)-based immunoassay for quantifying antibodies against cyclic citrullinated peptides
KR101979865B1 (ko) 루프스 안티코아귤란트의 검출방법
Garinet et al. Differential interferences of hemoglobin and hemolysis on insulin assay with the Abbott Architect®-Ci8200 immunoassay
Wolf et al. Hemolysis and IgA‐antibodies against tissue transglutaminase: When are antibody test results no longer reliable?
Çalcı et al. Comparison of the performance of second (Fast TSH) and third (HYPERsensitive TSH) generation automated TSH immunoassays in healthy euthyroid subjects.
BR112023015991A2 (pt) Métodos para detecção de cadeia leve de neurofilamento no plasma e no líquido cerebrospinal
Denimal et al. Evaluation of the new restandardized 25-hydroxyvitamin D assay on the iSYS platform
Marti et al. Determination of carbohydrate‐deficient transferrin in human serum by two capillary zone electrophoresis methods and a direct immunoassay: Comparison of patient data
Ismail On the interpretation of affirmative follow-up tests in immunoassays: what must not be done?
Kopke et al. Response to letter to editor regarding Variability of symmetric dimethylarginine in apparently healthy dogs
Younes et al. Performance Evaluation of a New Fluorescent-Based Lateral Flow Immunoassay for Quantification of Hemoglobin A1c (HBA1c) in Diabetic Patients
Nasser et al. Inter-method variability of hepatitis B surface antigen quantification in a cohort of Egyptian patients with chronic hepatitis B virus